Stoke Therapeutics, Inc. STOK Depreciation
Depreciation at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s depreciation?
- Stoke Therapeutics, Inc. (STOK) reported depreciation of $439K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s depreciation changed year-over-year?
- Stoke Therapeutics, Inc.'s depreciation decreased by 8.0% year-over-year, from $477K to $439K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s depreciation?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s depreciation has grown at a 16.1% compound annual growth rate (CAGR), from $974K to $1.77M.